Evidence map›Paper›PMID 34050875›Full record

ArticleActa parasitologica2021

The High Potency of Green Synthesized Copper Nanoparticles to Prevent the Toxoplasma gondii Infection in Mice.

Aishah E Albalawi, Abdullah D Alanazi, Mohamed S Alyousif, Azadeh Sepahvand, Katrin Ebrahimi, Massumeh Niazi, Hossein Mahmoudvand

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Acta parasitologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Anti-Advanced biomedical research · 2026
    Article
  3. Article
  4. Vaccines · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. The role ofFrontiers in cellular and infection microbiology · 2023
    Article
  10. Review
  11. Evaluating The Therapeutic Effect of 2-Nitroimidazole onIranian journal of pharmaceutical research : IJPR
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Aishah E AlbalawiDepartment of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Abdullah D AlanaziFaculty of Science and Humanities, Department of Biological Sciences, Shaqra University, P.O. Box 1040, Ad-Dawadimi, 11911, Saudi Arabia.
Mohamed S AlyousifDepartment of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Azadeh SepahvandDepartment of Laboratory Sciences, Lorestan University of Medical Sciences, Khorramabad, Iran.
Katrin EbrahimiDepartment of Biology, Payame Noor University, Tehran, Iran.
Massumeh NiaziDepartment of Laboratory Sciences, Lorestan University of Medical Sciences, Khorramabad, Iran.
Hossein MahmoudvandRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. dmahmodvand@gmail.com.ORCID http://orcid.org/0000-0003-4194-393X
Lorestan University of Medical Sciences · IRKing Saud University · SAPayame Noor University · IRShaqra University · SAUniversity of Tabuk · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNowadays, due to the lack of an effective vaccine to prevent the toxoplasmosis, chemotherapy with the combination of pyrimethamine and sulfadiazine is considered as the "gold standard" treatment for toxoplasmosis. Recent reports have exhibited that these synthesized chemical drugs are associated with some serious side effects. The present study aims to evaluate the prophylactic effects of copper nanoparticles (CuNPs) green synthesized by Capparis spinosa fruit methanolic extract alone and combined with atovaquone against chronic toxoplasmosis induced by the Tehran strain of Toxoplasma gondii in mice

methodsMice were then orally administrated with CuNPs at the doses of 2 and 4 mg/kg/day and in combined with atovaquone 50 mg/kg for 14 days. Male BALB/c mice were divided into two seven groups include C1 (non-treated non-infected); C2 (treated with normal saline); C3 (Infected mice treated with atovaquone 100 mg/kg/day); Ex1 (treated with CuNPs 2 mg/kg/day); Ex2 (treated with CuNPs 4 mg/kg/day); Ex3 (treated with CuNPs 2 mg/kg/day + atovaquone 50 mg/kg/day); Ex3 (treated with CuNPs 4 mg/kg/day + atovaquone 50 mg/kg/day). On the 15th day, the mice were infected with the intraperitoneal inoculation of 20-25 tissue cysts from the Tehran strain of T. gondii. The mean numbers of brain tissue cysts and the mRNA levels of IL-12, IFN-γ, and inducible nitric oxide synthase (iNOS) in mice of each tested group were measured.

resultsCuNPs were green synthesized by C. spinosa methanolic extract. Scanning electron microscopy showed that the particle size of CuNPs was 17 and 41 nm with maximum peak at the wavelength of 414 nm. The mean number of T. gondii tissue cysts in mice of tested groups of Ex1, Ex2, Ex3, and Ex4, significantly decreased as a dose-dependent response compared with control group. Moreover, in similar to the control group C3, no T. gondii tissue cysts was observed in mice of experimental group Ex3 and Ex4. The mRNA levels of IFN-γ, IL-12, and iNO was measured in mice of all tested groups. The mRNA levels of IFN-γ, IL-12, and iNO was increased in all mice of experimental groups in comparison with the control group C2; however, a significant enhancement was detected in mRNA level of IFN-γ, IL-12, and iNO in the tested groups of Ex3 and Ex4 when compared with control group C3.

conclusionThe obtained results revealed the high potency of CuNPs alone and combined with atovaquone to prevent toxoplasmosis in mice. Although, the prophylactic effects of CuNPs and other properties, such as improved cellular immunity and low toxicity, are positive topics; however, more studies are required to approve these findings especially in clinical settings.

Indexed as

NanoparticlesToxoplasmaToxoplasmosisToxoplasmosis, AnimalAnimalsCopperIranMaleMiceMice, Inbred BALB CCopperChronic toxoplasmosisIn vivoMicemRNANanomedicineToxoplasma gondii

Identifiers

PMID34050875
OpenAlexW3165248159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.